HIV Research & Clinical Practice

metrics 2024

Fostering collaboration for a brighter future in HIV care.

Introduction

HIV Research & Clinical Practice, published by Taylor & Francis Ltd, is an essential open-access journal dedicated to advancing the knowledge and understanding of HIV-related research and clinical practices. With an ISSN of 2578-7489 and E-ISSN 2578-7470, this acclaimed journal is committed to disseminating cutting-edge studies and innovative treatment strategies within the infectious diseases and pharmacology fields, achieving a commendable Q2 ranking in both categories as of 2023. The journal's scope encompasses a broad range of topics from basic science to clinical application, providing a vital platform for researchers, clinicians, and students to exchange insights and foster collaboration. As an open-access publication since 2022, it ensures that high-quality research is accessible to a global audience, encouraging a greater understanding of HIV and its implications for public health. With its base in the United Kingdom and a convergence period from 2019 to 2024, HIV Research & Clinical Practice stands at the forefront of the fight against HIV/AIDS, making significant contributions to the clinical community and beyond.

Metrics 2024

SCIMAGO Journal Rank0.62
Journal Impact Factor1.70
Journal Impact Factor (5 years)1.70
H-Index54
Journal IF Without Self1.70
Eigen Factor0.00
Normal Eigen Factor0.08
Influence0.66
Immediacy Index0.10
Cited Half Life2.90
Citing Half Life6.70
JCI0.35
Total Documents839
WOS Total Citations109
SCIMAGO Total Citations4929
SCIMAGO SELF Citations210
Scopus Journal Rank0.62
Cites / Document (2 Years)2.15
Cites / Document (3 Years)1.86
Cites / Document (4 Years)1.85

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #158/272
Percentile 41.91
Quartile Q3
Infectious Diseases in Medicine
Rank #202/344
Percentile 41.28
Quartile Q3

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 98/132
Percentile 26.10
Quartile Q3
PHARMACOLOGY & PHARMACY
Rank 251/354
Percentile 29.20
Quartile Q3

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 100/132
Percentile 24.24
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 284/354
Percentile 19.77
Quartile Q4

Quartile History

Similar Journals

Current HIV/AIDS Reports

Leading the charge in HIV/AIDS knowledge dissemination.
Publisher: SPRINGERISSN: 1548-3568Frequency: 4 issues/year

Current HIV/AIDS Reports, published by Springer, is a distinguished scholarly journal that addresses critical developments in the field of HIV/AIDS research. As a leading publication within the Q1 quartiles for both Infectious Diseases and Virology, it serves as an essential platform for researchers and healthcare providers aiming to advance knowledge and practices related to HIV prevention, treatment, and care. With a commitment to publishing innovative studies, reviews, and clinical guidelines, this journal fosters a comprehensive understanding of the complexities surrounding HIV/AIDS. The journal enjoys a robust reputation, evidenced by its impressive Scopus rankings, including a rank of #69 in Infectious Diseases and #21 in Virology, placing it in the top echelons of its field. With an open-access model, *Current HIV/AIDS Reports* significantly enhances the accessibility of crucial research findings to a global audience, driving progress in HIV/AIDS knowledge and public health.

JNCI Cancer Spectrum

Advancing cancer research for a brighter tomorrow.
Publisher: OXFORD UNIV PRESSISSN: Frequency: 6 issues/year

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

AIDS PATIENT CARE AND STDS

Pioneering research for better patient care.
Publisher: MARY ANN LIEBERT, INCISSN: 1087-2914Frequency: 12 issues/year

Welcome to AIDS PATIENT CARE AND STDS, a leading journal dedicated to the comprehensive exploration of clinical practices, research advancements, and public health strategies centered around HIV/AIDS and sexually transmitted diseases. Published by Mary Ann Liebert, Inc., this esteemed journal has been at the forefront of disseminating critical findings since 1996, contributing to a robust understanding of the complexities surrounding these global health issues. With an impressive impact factor reflected in its 2023 Q1 quartile rankings in both Infectious Diseases and Public Health, Environmental and Occupational Health, the journal stands out among its peers, ranking at the 95th percentile for Public Health and 91st percentile in Infectious Diseases. Researchers, healthcare professionals, and students will benefit from its rich content, comprehensive studies, and critical reviews that aim to improve care practices and health outcomes. With a clear commitment to fostering knowledge and collaboration in the field, AIDS PATIENT CARE AND STDS is an essential resource for those dedicated to combating these pressing health challenges.

AJAR-African Journal of AIDS Research

Empowering Knowledge, Transforming Lives
Publisher: TAYLOR & FRANCIS LTDISSN: 1608-5906Frequency: 4 issues/year

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

AIDS AND BEHAVIOR

Transforming knowledge into action against HIV/AIDS.
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 1090-7165Frequency: 12 issues/year

AIDS AND BEHAVIOR, published by SPRINGER/PLENUM PUBLISHERS, is a leading scholarly journal dedicated to the interdisciplinary study of HIV/AIDS, focusing particularly on the behavioral aspects of the epidemic. With an impressive impact factor reflected in its Q1 rankings across key categories including Infectious Diseases, Public Health, and Social Psychology, this journal serves as a vital resource for researchers, clinicians, and public health professionals. It encompasses a wide scope of research, from the psychosocial factors influencing HIV transmission to innovative interventions that promote safe practices. Although it does not offer open access, the journal's rigorous peer-review process ensures the dissemination of high-quality, impactful research. Covering data from 1997 to 2024, AIDS AND BEHAVIOR is positioned at the forefront of advancements in the field, making it an essential addition to any academic library and a must-read for those involved in combating HIV/AIDS.

Transgender Health

Innovating practices to enhance the well-being of transgender individuals.
Publisher: MARY ANN LIEBERT, INCISSN: 2688-4887Frequency: 6 issues/year

Transgender Health is an esteemed academic journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of transgender health and well-being. With an ISSN of 2688-4887 and an E-ISSN of 2380-193X, the journal aims to disseminate high-quality, peer-reviewed research that addresses the health disparities and unique medical needs of transgender individuals. Recognized for its scholarly impact, Transgender Health boasts a Q1 ranking in Gender Studies and a Q2 ranking in Medicine (miscellaneous) as of 2023, reflecting its significance in both social and clinical arenas. The journal's rigorous approach is evident in its Scopus rankings, placing it in the top 15% for Gender Studies and the top 32% for miscellaneous medical disciplines. Published continuously from 2016 to 2024, it is an essential resource for researchers, healthcare professionals, and students aiming to contribute to the discourse on transgender health. For those interested in critical developments, this journal remains a primary source of cutting-edge research and innovative practices without the constraints of open access, making it a valuable addition to the academic landscape.

JNCI-Journal of the National Cancer Institute

Leading the charge in cancer innovation and discovery.
Publisher: OXFORD UNIV PRESS INCISSN: 0027-8874Frequency: 12 issues/year

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Advancing knowledge in HIV/AIDS research.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1525-4135Frequency: 15 issues/year

JAIDS - Journal of Acquired Immune Deficiency Syndromes, is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamics of HIV/AIDS and its broader implications in the fields of infectious diseases and pharmacology. With an esteemed impact factor that places it in the prestigious Q1 category for both Infectious Diseases and Pharmacology (medical) as of 2023, this journal aims to provide a platform for groundbreaking research, clinical findings, and innovative therapies relevant to the management and prevention of HIV/AIDS. The journal's rigorous editorial standards and commitment to advancing knowledge make it an essential resource for researchers, healthcare professionals, and students invested in the global response to AIDS. Although the journal does not currently offer open access options, it remains instrumental in disseminating high-quality research that shapes clinical practices and policy developments in the field.

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE

Innovating HIV care with cutting-edge research and collaboration.
Publisher: AOSISISSN: 1608-9693Frequency: 1 issue/year

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, published by AOSIS, stands as a vital resource in the field of Infectious Diseases, particularly focusing on HIV medicine. With an ISSN of 1608-9693 and E-ISSN 2078-6751, this Open Access journal has been dedicated to disseminating cutting-edge research since 2001, ensuring that findings are accessible to a global audience of researchers, healthcare professionals, and students. Operating out of South Africa, the journal has earned a position in the Q3 quartile for Infectious Diseases, reflecting its commitment to advancing the understanding and treatment of HIV-related issues. Its Scopus ranking, presently at #207 out of 344, further emphasizes its scholarly influence, positioning it as an essential publication within the medical community. The journal aims to foster collaboration and innovation in HIV research and practice, bridging gaps between theory and real-world application to improve health outcomes in southern Africa and beyond.

Oncology Letters

Unveiling the Latest in Cancer Research and Innovations
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.